The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."
West Virginia passes a law enabling optometrists to use ophthalmic lasers, providing essential eye care services for patients, especially in rural areas, and increasing access for Medicare beneficiaries. Source: Optometric Management
OcuSciences, Inc. has developed an innovative device, the OcuMet Beacon, uniquely designed for infrared and autofluorescence retinal imaging, with FDA clearance. Learn more at www.ocusciences.com. Source: Optometric Management
OcuSciences, Inc. announced at ARVO that the FDA has granted marketing clearance for its flagship device, the OcuMet Beacon, a confocal scanning ophthalmoscope designed for infrared and autofluorescence imaging of the retina.
The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.
Retinal Physician
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Eyenovia's late-stage study for near-sightedness in children with an experimental drug-device combination has been discontinued after failing to slow myopia progression, leading to consideration of strategic alternatives.
"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."
A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.